What If Ventures

www.whatif.vc

VCMatch tracks What If Ventures as an investor focused on Digital Health, Healthtech, and Biotech companies, Pre-Seed and Seed rounds, United States markets, and $2k to $100m check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$2k to $100m

Stages

Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage

Focus Areas

Digital Health, Healthtech, Biotech

Geography

United States

Investment Thesis

What If Ventures deploys capital to companies that ‘radically transform’ the human experience—primarily by improving mental health and broader disruptive healthcare—and is now expanding into defense/industrial technology under the banner of ‘Health and Freedom.’ The firm is mission-driven (founded out of the founder’s personal recovery), emphasizes investing in life-changing, stigmatized or under-capitalized healthcare solutions (including psychedelics, biomarkers/personalized psychiatry, digital therapeutics and biotech), and couples that mission orientation with a pragmatic, data-driven approach to valuation and unit economics.

Is What If Ventures right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

What If Ventures is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Digital Health, Healthtech, Biotech, and Pharma, especially across United States, with public check-size signals around $2k to $100m.

Focus statement

The firm is focused on disruptive healthcare with a heavy concentration in mental health (including biotech, digital therapeutics and psychedelics) and is expanding into defense and industrial technology — summarized on the site as 'Investing in Health and Freedom.'

Value Add

Founder-led mission rooted in lived experience: the firm was 'born out of my personal struggle with addiction' and the founder explicitly combines his recovery experience with investing to back mental-health solutions.
Track record and scale via syndicate/LP base: 'Over $100mm invested into more than 85 startups since 2020' and growth from a 12-person syndicate to 'over 4,100 investors' (4,000+ LPs referenced elsewhere).
Domain crossover: deep healthcare focus plus founder’s West Point + Aerospace & Defense banking background enables differentiated deal flow and operational/DoD/primes relationships for defense tech companies.
Willingness to invest in stigmatized or emerging modalities (e.g., psychedelics, personalized psychiatry/biomarkers) — portfolio includes Atai, Beckley Psytech, Alto Neuroscience and others.
Valuation discipline and analytic approach: the firm publishes regular 'Disruptive Healthcare' valuation reports and explicitly prioritizes 'profitability — or a path to profitability' and unit economics when underwriting deals.